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Abstract
Background: Underlying coinfections may complicate infectious disease states but commonly go unnoticed because
an a priori clinical suspicion is usually required so they can be detected via targeted diagnostic tools. Shotgun
metagenomics is a broad diagnostic tool that can be useful for identifying multiple microbes simultaneously especially
if coupled with lymph node aspirates, a clinical matrix known to house disparate pathogens. The objective of this study
was to analyze the utility of this unconventional diagnostic approach (shotgun metagenomics) using clinical samples
from human tularemia cases as a test model. Tularemia, caused by the bacterium Francisella tularensis, is an emerging
infectious disease in Turkey. This disease commonly manifests as swelling of the lymph nodes nearest to the entry of
infection. Because swollen cervical nodes are observed from many different types of human infections we used these
clinical sample types to analyze the utility of shotgun metagenomics.
Methods: We conducted an unbiased molecular survey using shotgun metagenomics sequencing of DNA extracts
from fine-needle aspirates of neck lymph nodes from eight tularemia patients who displayed protracted symptoms.
The resulting metagenomics data were searched for microbial sequences (bacterial and viral).
Results: F. tularensis sequences were detected in all samples. In addition, we detected DNA of other known pathogens
in three patients. Both Hepatitis B virus (HBV) and Human Parvovirus B-19 were detected in one individual and Human
Parvovirus B-19 alone was detected in two other individuals. Subsequent PCR coupled with Sanger sequencing verified
the metagenomics results. The HBV status was independently confirmed via serological diagnostics, despite evading
notice during the initial assessment.
Conclusion: Our data highlight that shotgun metagenomics of fine-needle lymph node aspirates is a promising clinical
diagnostic strategy to identify coinfections. Given the feasibility of the diagnostic approach demonstrated here, further
steps to promote integration of this type of diagnostic capability into mainstream clinical practice are warranted.
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Background
Underlying coinfections in primary infectious disease are
an important variable to consider but are commonly
undetected. A growing body of literature points to the high
occurrence (10–50%) of coinfections [1–5], and > 75% of
coinfections from diverse origins have an overall negative
impact on human health [6]. Underlying coinfections com-
plicate disease presentation [7, 8] and the ability to detect
their presence is highly relevant to inform medical treat-
ment. The under-diagnosis of coinfections is due, among
other things, to a lack of clinical suspicion, overlapping
symptoms, and/or the fact that traditional tools have lim-
ited ability to identify coinfections in the absence of a priori
knowledge. Thus, exploration of new diagnostic strategies
is necessary to advance the understanding of the contribu-
tion of coinfections to infectious disease manifestations
and treatment responses.
Significant advances in next generation sequencing have
recently made metagenomics, an unbiased shotgun method
of analysis, a widely used tool in just about all areas in
biology, including infectious disease diagnostics [9, 10].
Metagenomics is powerful for its ability to diagnose unsus-
pected microbial agents [11]. It directly analyzes samples in
their entirety, which removes the requirement for a priori
knowledge to obtain comprehensive information. In this
capacity, metagenomics surpasses the limits encountered
with traditional diagnostics.
Many infectious disease-causing microbes are consid-
ered foreign by the host immune system and, therefore,
are actively routed to the lymph nodes. As a consequence,
lymph nodes capture and house disparate microbes [12]
regardless of their transmission route or ability to persist
within the host. In a non-disease state, cervial lymph
nodes are normally microbe-free environments [12].
Because of these unique attributes, lymph nodes make an
ideal clinical target to detect underlying coinfections.
F. tularensis is the causative agent of the zoonotic disease
tularemia and it can infect humans by several routes,
including the ingestion of contaminated water or food.
Exposure to F. tularensis-contaminated water [13, 14],
blood-feeding vectors [15], or, on rare occasion, aerosolized
particulates [16] each lead to distinct clinical forms of
tularemia: orophyryngeal, ulcergrandular, and respiratory
tularemia, respectively. In the rapidly developing nation of
Turkey, tularemia has been on the rise since 2009 and oro-
pharyngeal disease is the most common form [17]. This
form involves a sore throat and the swelling of cervical
lymph nodes. Antibiotic treatment is highly effective at sig-
nificantly shortening disease duration [17] and very little
evidence exists to support the idea that antibiotic resistant
F. tularensis strains are prevalent in Turkey [18]. Because
swollen cervical nodes are observed from many different
types of human infections occurring in Turkey [19], we
wanted to use cervical fine-needle aspirates of lymph nodes
from eight tularemia patients [20] as a test model to
analyze the utility of shotgun metagenomics to assess for
the presence of multiple infectious agents.
Methods
Direct whole-genome sequencing of clinical lymph node
samples
DNA extracts from fine-needle aspirates of lymph nodes
from eight de-identified tularemia patients in Turkey [20]
were processed in the Pediatric Infectious Disease Unit of
the Faculty of Medicine, Hacettepe University hospital in
Ankara, Turkey and subjected to direct metagenomics
sequence analysis. The human fine-needle aspirates were
collected as part of the medical workup for tularemia
diagnosis and, therefore, were not subject to Institutional
Review Board regulations; the residual aspirate materials
were de-identified and donated to this study. The patient
samples were selected based on sufficient levels of F.
tularensis DNA as confirmed by PCR; F. tularensis isolates
were not obtained from these eight patients. To prepare
the libraries for metagenomics sequencing, 100 μL of
DNA extract per clinical sample was processed using the
KAPA Library Preparation Kits with Standard PCR
Library Amplification/Illumina series (KAPA biosystems,
Boston MA, code KK8201) with modifications (Additional
file 1 - Methods); this kit is designed to target double
stranded DNA and, therefore, RNA sequences were likely
not captured in our study.
Bioinformatic analyses
WGS data from the eight samples were analyzed using the
metagenomics data analysis method MetageniE (https://
github.com/ngsclinical/metagenie), as previously described
[21] and with the following specific settings. We utilized
quality filtration (PHRED quality score > 15, minimum
length > 50, low complexity (dust) and removal of dupli-
cates) with Prinseq [22]. The human filtration module
processed reads with BWA [23] against a human reference
genome (Hg19) to remove human reads, and the pathogen
detection module utilized global aligner BWA and local
aligner BLAT [24] on the filtered reads against bacterial
and viral databases (Build 56 downloaded from ftp://
ftp.ncbi.nih.gov/refseq/release/). Genome coverage of the
mapped reads was visualized with Tablet [25]. The results
were further confirmed with the metagenomic pipeline
SURPI [26]. Paired end raw reads were concatenated and
processed [26] with SURPI in “fast” mode with a d_NT_a-
lignment value of 6. Read counts were tabulated from the
SNAP [27] alignment against their custom reference
genome database. Bioinformatics data were curated for the
presence of bacteria and viruses. All raw reads were sub-
mitted to NCBI as Sequence Read Archives (SRA) (Table 1).
To assess for inadvertent contamination from the environ-
ment of the sequencing facility, we bioinformatically
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analyzed other complex clinical and environmental samples
processed at the same (Translational Genomics Research
Institute; TGen) facility as the Turkish clinical samples.
These samples were prepared and subsequently sequenced
at the same time as the Turkish clinical samples utilizing
the same reagents.
Molecular confirmation of pathogens detected by
bioinformatics analysis
To test for the presence of low level hepatitis B (HBV)
and human parvovirus B19 (B19) in all eight clinical sam-
ples, we employed a nested PCR approach using assays
developed using information from previous publications
[28, 29] (Table 2), and confirmed the pathogen detection
by Sanger sequencing of the final PCR amplicons. Nested
PCRs for HBV and B19 were accomplished by two PCR
amplification steps that employed the use of external
primers followed by amplification with internal primers.
Amplification of the PCR product by the external primers
was achieved in 10 μL reaction volumes using real-time
PCR with the following conditions: 1 μL DNA extract, 2×
SYBR green master mix (Life Technologies, Grand Island,
NY) diluted with molecular grade water to bring final con-
centration to 1×, and 0.2 uM primers (Integrated DNA
Technologies, San Diego, CA). A real-time PCR 7900
instrument (Life Technologies, Grand Island, NY) was pro-
grammed with the following protocol: 95 °C for 10 min to
release the polymerase antibody, followed by 40 cycles of
95 °C for 15 s and 55 °C for 60 s. The PCR products from
the external primers were diluted to 1:1000 prior to being
used as a template for the next amplification step involving
internal primers. Amplification of PCR with the internal
primers (Table 2) was achieve in 10 μL reactions using
conventional PCR with the following conditions: 1 μL of
diluted PCR product (1:1000) as template, 1× PCR
buffer, 2.5 mM MgCl2, 0.2 mM dNTPs, 0.16 U/ μL
Platinum® Taq polymerase (Invitrogen, Carlsbad, CA,
USA), and 0.2 μM of each primer. The thermocycle
protocol was as follows: 94 °C for 10 min to release
the polymerase antibody, followed by 35 cycles of
94 °C for 30 s, 55 °C for 30 s, and 72 °C for 60 s.
To confirm the true positive detection of HBV and B19
DNA from the clinical samples by internal primers of the
nested approach, we generated Sanger sequences of the
PCR amplicons. Sequencing was performed directly on
the parvovirus B19 PCR product (251 bp) generated from
the final B-19 internal primers (Table 2). The internal
primers for HBV PCR generated a short amplicon (only
74 bp) within which only 37 bp represented the original
HBV sequence present as the starting template in the clin-
ical sample. Due to the exceptionally short HBV fragment
Table 1 F. tularensis positive clinical samples
NAU ID Patient ID WGS Bioinformatic sequence (read counts) PCR status
NCBI accession # R. picketti P. acnes F. tularensis HBV Parvovirus B-19 F. tularensis HBV Parvovirus B-19
F0739 3 SRR1925378 10 119 1960 30 2 + + +
F0742 6 SRR1925905 371 14 3265 0 6 + – +
F0741 5 SRR1925811 157 2 131 0 2 + – –
F0737 1 SRR1924572 89 1 260 0 0 + – –
F0738 2 SRR1925227 167 8 474 0 0 + – –
F0744 8 SRR1927285 3 7 1060 0 0 + – –
F0745 9 SRR1928041 38 0 835 0 0 + – –
F0749 13 SRR1931205 106 2 950 0 0 + – –
Table 2 Primer Sequence for nested PCR amplification
Pathogen Target Nested PCR scheme Primer Sequence Amplicon size Sanger Sequence target Gene Target Published
Hepatitis B_F1 Outer Forward GGGAGGAGATTAGGTTAA 216 bp NA DistalX/pre-C gene Chakravarty et
al., 2002
Hepatitis B_R1 Outer Reverse GGCAAAAAAGAGAGTAACTC
Hepatitis B_F1 Internal Forward *agctttccttgtttcgaattttataaTCTG
TTCACCAGCACCAT
74 bp 37 bases
Hepatitis B_R1 Internal Reverse AGGCTTGAACAGTAGGACA
HpB19_F1 Outer Forward CAAAAGCATGTGGAGTGAGG 398 bp NA VP1 Koch and
Adler et al.,
1990HpB19_R1 Outer Reverse CTACTAACATGCATAGGCGC
HpB19_F1 Internal Forward CCCAGAGCACCATTATAAGG 288 bp 251 bases Yamakawa
et al., 1995
HpB19_R1 Internal Reverse GTGCTGTCAGTAACCTG
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size, we used a novel molecular strategy that incorporated
this small PCR product into a larger fragment resulting in
a 356 bp fragment (Additional file 1: Methods Figure S1),
which was directly sequenced. The final HBV and B19
PCR products were treated with ExoSAP-IT (Affymetrix,
Santa Clara, CA, USA) using 1 μL of ExoSAP-IT per 5 μL
of PCR product under the following conditions: 37 °C for
15 min, followed by 80 °C for 15 min. Treated products
were then diluted in the range of 1:2 to 1:5 depending on
amplicon intensity (as determined by agarose gel electro-
phoresis). HPV-B19 was sequenced in both directions
using BigDye® Terminator v3.1 Ready Reaction Mix (Life
Technologies Applied Biosystems, Foster City, CA, USA)
with the same forward and reverse primers from the initial
PCR. HBV was sequenced in one direction with a forward
primer (Elong-fwd356, ATATATTGTAACTAAACTA
TGTGCCGCTGA) that targeted the elongated region
(Additional file 1: Methods Figure S1). We used 10 μL vol-
umes for sequencing reactions containing the following
reagents (given in final volumes): 3 μL of 5× Sequencing
Buffer, 1 μL BigDye® Terminator v3.1 Ready Reaction Mix,
1 μL of a 10 μM primer stock, and 5 μL diluted PCR prod-
uct. The following thermocycling conditions were used:
96 °C for 20 s, followed by 30 cycles of 96 °C for 10 s, 50 °
C for 5 s, and 60 °C for 4 min. An ethanol precipitation
technique was used to clean and precipitate the DNA pel-
let, and Sanger sequencing was carried out using an AB
3130xl® automated genetic analyzer (Life Technologies,
Grand Island, NY); sequence chromatograms were edited
manually in Sequencher 5.0 (Gene Codes, Ann Arbor,
MI). Sequences were blasted in NCBI to search for perfect
sequence matches with published Hepatitis B and Human
Parvovirus B19 data.
As a positive control for our molecular approach, we
constructed a synthetic sequence of 614 bp (Integrated
DNA Technologies, San Diego, CA) encoding known
HBV and B19 sequence regions targeted by the pub-
lished assays [28, 29]. To confidently differentiate real
signal from false signal due to potential cross
contamination with our synthetic positive control, we
engineered six deliberate point mutations not observed
in nature within the PCR assay targets of the synthetic
positive control (Additional file 1: Methods Figure S2).
With this design, we were able to discern true positives
from false positives after sequencing was performed
based on the presence of the deliberate mutations.
Water was added in place of template as negative
controls, and all sample reactions were conducted in
replicates of two.
Results
Metagenomics analysis of fine-needle aspirates of cervical
lymph nodes from tularemia patients identified underlying
coinfections (HBV and parvovirus B19). The true burden
of coinfection may have been underestimated by not ac-
counting for RNA viruses. Metagenomic analysis identi-
fied the presence of F. tularensis in all eight clinical
samples when analyzed by both MetaGeniE and SUPRI.
In addition, both analysis search methods detected other
microbes in the same subset of patient samples (Parvo-
virus B19 in patients 3, 5, and 6, and HBV positive in pa-
tient 3, see Table 1). When combining total sequencing
reads from all eight clinical samples, we obtained a total of
787,568,687 reads with 99.6% (784,495,044) matching hu-
man DNA, 0.31% unknown (2,465,280), and 0.039%
(305,738) matching bacteria (Fig. 1). Among 305,738 reads
from bacteria, 8848 reads matched F. tularensis, which
comprised 2.89% of total bacterial reads (Fig. 1). This
composition profile of extremely high levels of human
DNA and low-level F. tularensis DNA in these clinical
samples is consistent with our real-time PCR data (data
not shown). Despite this extreme disproportionate ratio
between human vs pathogen DNA species, 1000×
sequence coverage provided enough sequences of F. tular-
ensis, HBV, and parvovirus at high sequence match iden-
tity to solidly confirm the presence of these pathogens in
specific clinical samples (Table 1). The other detected
non-Francisella bacterial reads were classified as errors
Fig. 1 Direct sequence of eight clinical lymph node aspirate samples. Pie chart indicate 787,568,687 total reads compiled across the eight
samples, providing percent partition of DNA sequences originating from human, unknown, unspecified bacterial, and Francisella tularensis. Read
length were 100 bp at 1000× coverage depth
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due to poor sequencing match identities with reference
bacteria in published databases.
Our metagenomics analysis also detected non-pathogenic
commensal skin bacteria, Propionibacterium acnes, which
is likely real (Table 1) and is probably an incidential conse-
quence of the fine-needle aspiration process itself, which in-
volves the direct puncture of the skin [30]. We also
detected Ralstonia picketti sequence in all eight patient
samples (Table 1). Many clinical reagents, including
ultra-pure water systems, have been reported to be contam-
inated with Ralstonia species [31, 32] and we hypothesize
that this a likely source for our samples. Since R. picketti
and P. acnes are known to have little clinical consequence
[33, 34], no molecular confirmation was conducted on
these organisms.
Our metagenomics analysis yielded high quality matches
for 8848 sequencing reads of F. tularensis generated from
all eight samples, which represents a very small fraction of
the F. tularensis genome (see Table 1, Additional file 1:
Methods Figure S3). Despite limited data for this analysis,
more data could have been captured by this metage-
nomics strategy by increasing the coverage depth for
which the sequencing was generated (i.e. > 1000× cover-
age). We found no evidence for F. tularensis, HBV, human
parvovirus B19, and Ralstonia species among other
clinical samples prepared and sequenced at the TGen
sequencing facility, suggesting that the DNA sequence of
these four microbes did not originate from the environ-
ment nor commercial reagents used in this facility at the
time lymph node aspirates were processed.
Standardized traditional diagnostics independently con-
firmed the HBV coinfection in patient 3 that was initially
detected through metagenomics. Active infection with
HBV was confirmed in patient 3 via a serological diagnos-
tic test, despite being missed by prior clinical examination.
This confirmation was communicated using a method
that retained the integrity of the patient de-identification
system. No further information in respect to the stage of
disease for this patient was obtained.
Molecular methods confirmed the presence of DNA
sequence from multiple pathogens in three of the eight
clinical samples, consistent with coinfection in these pa-
tients. We tested all eight samples that were PCR-positive
for F. tularensis for the presence of parvovirus B19 and
HBV. Through a combination of nested PCR followed by
Sanger sequencing using parvovirus B19-specific primers
[29], we confirmed detection from patients 3 and 6 but
not 5 (Table 1). The 251 bp B19-specific amplicon from
patients 3 had 100% sequence identity with published
strains of human parvovirus B19 encoding a VP1 gene
(EU478584), and the B19-specific amplicon from patient 6
had 99% sequence identity to published strains. This com-
parison identified a single base mutation that did not
match any of the six deliberate mutations engineered in
the synthetic positive control. Thus, this mutation either
reflects the sequence of the original template or arose as
an artifact introduced during PCR and sequencing
process. An HBV-specific amplicon was generated from
patient 3 and not from the other seven samples (Table 1).
HBV-specific primers amplified a 37 bp fragment in pa-
tient 3 that perfectly matched published strains for C12 X
protein (X) and core protein (C) genes (KP309751).
Not all pathogens initially detected by bioinformatics
were confirmed through molecular methods. Parvovirus
B19 was detected in patient 5 by metagenomics but not
by our nested PCR Sanger sequencing molecular tech-
niques. Although this suggests that the PCR assay used
in our study is less sensitive than deep sequencing tech-
nology, it is thought that deep sequence Illumina output
is nearly comparable to well optimized real-time PCR
assay [35]. Thus, the sensitivity difference more likely
stems from the technical differences between the two
detection strategies. Unlike real-time PCR, which used
1 μL of DNA extract per reaction, metagenomics se-
quencing captured information from 100 μL of DNA ex-
tract. The results suggest that the larger volume of
template enabled the capture of enough low-level parvo-
virus DNA in patient 5 for successful sequencing that
was missed using the PCR strategy.
Discussion
The importance of identifying underlying coinfection(s) is
gaining greater appreciation [5, 6] but obtaining such infor-
mation still remains challenging. We demonstrate an
effective strategy to capture existing coinfections by using
fine-needle aspirates obtained from cervical lymph nodes
from tularemia patients. Other clinical sample types may
be inferior at detecting coinfections as suggested by our
finding that F. tularensis was PCR negative in blood
samples of all eight patients (data not shown) but positive
from the lymph node aspirates [20]. Using the metage-
nomics approach, we were able to detect diverse organisms
(bacterial and viruses) that greatly differed in transmission
routes and host persistence, indicating a lack of bias based
on these differing biological parameters.
Surveying for pathogens from a clean microbial envir-
onment, such as lymph nodes, may be a good approach
to diagnose clinically relevant microbes. However, not all
diagnoses necessarily reflect active disease or an infec-
tion that has clinical relevance. There are pathogens,
including parvovirus B19 DNA, that are never cleared
but, rather, continue to persist in a dormant state in the
host [36–38]. Studies have documented that parvovirus
B19 DNA sequence is detectable, albeit at very low
levels, from a wide range of human clinical samples
(skin, synovium, tonsil, heart or liver [36] and bone
marrow [39]) years after seroconversion. Although such
surveys have not been conducted in lymph nodes,
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fine-needle lymph node aspirates contain cellular ma-
terial, including immune cells continuously migrating
between these nodes, the circulation system, and the
bone marrow [40]. For this reason, we cannot con-
clude that the parvovirus B19 detected in three
pediatric patient samples in this study was the result
of acute infections. Initial patient medical examina-
tions did not note signs of active skin rashes (data
not shown). However, missed symptoms could be ex-
plained by the examination occurring during the early
or late phase of this acute disease. In short, metage-
nomic diagnostics is highly informative for detecting
unsuspected pathogens, but clinicians must continue
to apply judgement to determine if detected patho-
gens have clinical relevance and/or warrant treatment.
Although fine-needle aspirates of lymph nodes are
highly informative clinical samples, their availability
varies. In Turkey, fine needle aspiration is considered
routine as part of diagnosis and treatment for oropha-
ryngeal tularemia and other diseases affecting lymph
nodes [17, 41]. However, due to the clinical invasiveness
of lymph node aspiration, in other countries this ap-
proach may be reserved for only those patient cases with
lymphadenopathy of uncertain etiology.
Coinfections are not commonly considered when diag-
nosing and treating tularemia and, therefore, the clinical
significance of coinfections is uncertain. Our results,
however, indicate that coinfections are not rare in tular-
emia patients in Turkey. In fact, the rates of HBV and
human parvovirus in our pediatric tularemia patients co-
incide well within the overall prevalence rates of these
two diseases in the general Turkish population (10 and
21%, respectively) providing some indirect evidence that
the detection could be unrelated to the acute F. tularen-
sis infection [42, 43]. Very little is known regarding the
effects of coinfection on clinical manifestation of tular-
emia and it is beyond the scope of this study to glean
insight as to the clinical significance of tularemia
patients with the identified coinfections.
Conclusions
Our study reveals that shotgun metagenomics targeting
fine-needle lymph node aspirate samples is a promising
clinical diagnostic strategy to identify underlying coin-
fection in primary disease as demonstrated by our ability
to simultaneously detect F. tularensis and possible coin-
fections. Other clinical specimens such as blood may not
be as informative for this purpose. In-depth exploration
of new broad diagnostic methods that identify multiple
microbes and possible coinfections is an important first
step to advance the understanding of disease manifesta-
tions and treatment responses, and to possibly promote
this capability into mainstream clinical practice.
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